RxDoctor Payments Data

Voltaire Velarde, MD

Internal Medicine · Vallejo, CANPI 1538243340

Payments from drug & device makers

$248in general payments, 2019–2025

Across 11 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$79
  • Novo Nordisk$56
  • Johnson & Johnson$28
  • Ironwood Pharmaceuticals, Inc$23
  • AbbVie$16
  • E.r. Squibb & Sons, L.L.C.$13
  • plus $33 from 3 others

What the payments were for

  • Food & beverage$23795%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$248 in reported general payments places this provider in the 55th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$323,441
Medicare patients
410
Services billed
3,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin140$213,468
FarxigaDapagliflozin Propanediol83$89,476
EliquisApixaban70$86,155
RybelsusSemaglutide37$76,155
OzempicSemaglutide26$41,119
JanuviaSitagliptin Phosphate22$26,448
ProliaDenosumab13$20,640
XareltoRivaroxaban18$19,921
MyrbetriqMirabegron15$16,353
LinzessLinaclotide11$15,946
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$12,714
VascepaIcosapent Ethyl18$11,952
Breo ElliptaFluticasone/Vilanterol16$8,408
Incruse ElliptaUmeclidinium Bromide14$8,032
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$6,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$79$213,468140 claims
Novo NordiskRybelsus, Ozempic$56$117,27463 claims
Johnson & JohnsonXarelto$28$19,92118 claims
AbbVieLinzess$16$15,94611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Vallejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →